Clinical trial

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

NCT02664935

Drugs and interventions used in this trial

11 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AZD4547 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Vistusertib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Crizotinib Normalized identity: crizotinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Selumetinib Normalized identity: selumetinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AZD5363 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sitravatinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AZD6738 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-05-13

PhasePHASE2

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Carcinoma, Squamous Cellcandidate · MONDO: squamous cell carcinoma

Adenocarcinomaverified · MONDO: adenocarcinoma

Interventions

AZD4547DRUG

VistusertibDRUG

PalbociclibDRUG · verified · RxNorm: palbociclib

CrizotinibDRUG · verified · RxNorm: crizotinib

SelumetinibDRUG · verified · RxNorm: selumetinib

DocetaxelDRUG · verified · RxNorm: docetaxel

AZD5363DRUG

OsimertinibDRUG · verified · RxNorm: osimertinib

DurvalumabDRUG · verified · RxNorm: durvalumab

SitravatinibDRUG

AZD6738DRUG

Sponsors & collaborators

University of Birminghamlead sponsor

Cancer Research UKcollaborator

AstraZenecacollaborator

Pfizercollaborator

Experimental Cancer Medicine Centrescollaborator

Mirati Therapeutics Inc.collaborator

Mapped research locations

LondonUnited Kingdom5 BirminghamUnited Kingdom2 ManchesterUnited Kingdom1 GlasgowUnited Kingdom1 CambridgeUnited Kingdom1 SheffieldUnited Kingdom1 EdinburghUnited Kingdom1 LeicesterUnited Kingdom1 LeedsUnited Kingdom1 OxfordUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02664935 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.